替尔泊肽联合基础胰岛素治疗中国2型糖尿病患者的疗效与安全性:SURPASS-CN-INS随机对照试验
SURPASS-CN-INS是一项在中国26家医院进行的40周双盲、多中心、随机、安慰剂对照3期试验,评估替尔泊肽联合基础胰岛素治疗血糖控制不佳的2型糖尿病患者的疗效与安全性。结果显示,替尔泊肽10 mg和15 mg组HbA1c较基线降幅显著大于安慰剂组,最常见不良事件为腹泻、食欲下降和上呼吸道感染,多为轻中度。
要点
- 替尔泊肽10 mg和15 mg联合基础胰岛素可显著改善中国2型糖尿病患者的血糖控制。
- 常见不良事件为腹泻、食欲下降和上呼吸道感染,胃肠道事件多为轻中度。
- 该研究为替尔泊肽在中国2型糖尿病患者的潜在治疗应用提供了证据。
核心结论
- 替尔泊肽联合基础胰岛素可改善血糖控制,且总体耐受性良好,支持其在中国2型糖尿病患者中的潜在治疗用途。
研究设计与样本
- SURPASS-CN-INS为40周、双盲、多中心、随机、安慰剂对照3期试验,在中国26家医院进行。
- 257例接受每日一次甘精胰岛素单用或联合二甲双胍(联用或不联用SGLT2抑制剂)且血糖控制不佳的2型糖尿病患者随机分配至替尔泊肽5 mg、10 mg、15 mg或安慰剂组。
- 主要终点为替尔泊肽10 mg或15 mg组与安慰剂组相比从基线至第40周HbA1c变化,在意向治疗人群中分析。
主要发现
- 替尔泊肽组最常见治疗中出现的不良事件包括腹泻、食欲下降和上呼吸道感染,胃肠道事件多为轻中度。
临床怎么用
- 对于基础胰岛素治疗血糖控制不佳的中国2型糖尿病患者,可考虑联合替尔泊肽以改善血糖控制。
- 使用替尔泊肽时需关注腹泻、食欲下降等不良事件,但多数为轻中度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on tirzepatide added to basal insulin in patients with type 2 diabetes in China are scarce. We aimed to evaluate the efficacy and safety of tirzepatide added to basal insulin in this population. METHODS: SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China. Participants aged 18 years or older with uncontrolled type 2 diabetes receiving once-daily insulin glargine alone or in combination with metformin with or without an SGLT2 inhibitor were randomly assigned (1:1:1:1) to once-weekly tirzepatide 5 mg, 10 mg, or 15 mg, or placebo by subcutaneous injection for 40 weeks, stratified by HbA1c (≤8·0% [≤64 mmol/mol] vs >8·0% [>64 mmol/mol]) and SGLT2 inhibitor use using an interactive web response system. Treatment assignment was masked from the study sponsor, investigators, site staff, clinical monitors, and patients until the end of the study by using identical packaging and injection devices for tirzepatide and placebo. The primary endpoint was change in HbA1c from baseline to week 40 for tirzepatide 10 mg or 15 mg versus placebo in all randomly assigned patients receiving at least one dose of treatment, excluding those who were enrolled inadvertently. Safety was evaluated in all randomly assigned patients receiving at least one dose of treatment. The study was registered with ClinicalTrials.gov, NCT05691712, and has been completed. FINDINGS: Between Feb 5, 2023, and July 1, 2024, 331 patients were screened, of whom 257 were randomly assigned to and received tirzepatide 5 mg (n=65), 10 mg (n=65), or 15 mg (n=63), or placebo (n=64). One patient in the tirzepatide 5 mg group and one in the placebo group were inadvertently enrolled and excluded from efficacy analyses. The mean age of 255 patients in the efficacy analysis set was 56·7 years (SD 10·5). 98 (38%) patients were female, and 157 (62%) patients were male. Patients receiving tirzepatide had greater reductions in HbA1c from baseline at week 40 than those receiving placebo (-2·39% [SE 0·13] in the 10 mg group, and -2·37% [0·13] in the 15 mg group vs -0·91% [0·12] in the placebo group; difference vs placebo -1·48% [97·5% CI -1·87 to -1·08; p<0·0001] for the 10 mg group and -1·45% [-1·85 to -1·06; p<0·0001] for the 15 mg group). The most common treatment-emergent adverse events among patients receiving tirzepatide were diarrhoea (17 [26%; 95% CI 17-38] of 65 in the tirzepatide 5 mg group, 24 [37%; 26-49] of 65 in the tirzepatide 10 mg group, and 23 [37%; 26-49] of 63 in the tirzepatide 15 mg group vs five [8%; 3-17] of 64 in the placebo group), decreased appetite (19 [29%; 20-41], 16 [25%; 16-36], and 20 [32%; 22-44] vs none [0%; 0-6]), and upper respiratory tract infection (13 [20%; 12-31], 11 [17%; 10-28], and 11 [18%; 10-29] vs ten [16%; 9-26]). Gastrointestinal adverse events commonly reported in other trials in the SURPASS programme, including diarrhoea, nausea (three [5%; 95% CI 2-13] in the tirzepatide 5 mg group, seven [11%; 5-21] in the tirzepatide 10 mg group, and seven [11%; 5-21] in the tirzepatide 15 mg group vs two [3%; 1-11] in the placebo group), and vomiting (four [6%; 2-15], six [9%; 4-19], and four [6%; 3-15] vs none [0%; 0-6]), were predominantly mild or moderate in severity. INTERPRETATION: Tirzepatide added to basal insulin improved glycaemic control and was generally well tolerated, providing evidence to support its potential therapeutic use in patients with type 2 diabetes in China. FUNDING: Eli Lilly and Company. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Guo L, Dong X, Ma J, et al. Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025. PMID: 41167231. doi:10.1016/S2213-8587(25)00248-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。